W. H. Wilson Tang, MD (@wilsontangmd) 's Twitter Profile
W. H. Wilson Tang, MD

@wilsontangmd

Opinions are my own.

ID: 852125154213801985

linkhttps://my.clevelandclinic.org/staff/5527-wai-hong-wilson-tang calendar_today12-04-2017 11:44:03

355 Tweet

1,1K Followers

8 Following

JACC Journals (@jaccjournals) 's Twitter Profile Photo

Emerging insights into the pathophysiologic basis, mode action and proof of concept features of renal assist devices in acute decompensated heart failure: bit.ly/3Q1AQjw #JACCHF #HeartFailure Pieter Martens W. H. Wilson Tang, MD

Emerging insights into the pathophysiologic basis, mode action and proof of concept features of renal assist devices in acute decompensated heart failure: bit.ly/3Q1AQjw

#JACCHF #HeartFailure <a href="/PieterMartensMD/">Pieter Martens</a> <a href="/WilsonTangMD/">W. H. Wilson Tang, MD</a>
NEJM (@nejm) 's Twitter Profile Photo

This phase 3 trial of patisiran, a small interfering RNA that targets hepatic production of the transthyretin protein, showed efficacy in treating transthyretin-mediated (ATTR) cardiac amyloidosis. Read the full APOLLO-B trial results: nej.md/4081o7o

JAHA (@jaha_aha) 's Twitter Profile Photo

Prognostic Value of Natriuretic Peptide Levels for Adverse Renal Outcomes in Patients With Moderate to Severe Acute Kidney Injury With or Without Heart Failure. #AHAJournals W. H. Wilson Tang, MD ahajrnls.org/40J9bcl

Prognostic Value of Natriuretic Peptide Levels for Adverse Renal Outcomes in Patients With Moderate to Severe Acute Kidney Injury With or Without Heart Failure. #AHAJournals <a href="/WilsonTangMD/">W. H. Wilson Tang, MD</a> ahajrnls.org/40J9bcl
EHJ Editor-in-Chief (@ehj_ed) 's Twitter Profile Photo

News in EHJ: Promises and challenges of targeting anti-CXCR3 autoantibodies in cardiovascular disease! academic.oup.com/eurheartj/adva… #cardioprotective #therapy #autoantibodies #G-protein #receptors #cardiotwitter European Society of Cardiology @ESC_journals

News in EHJ: Promises and challenges of targeting anti-CXCR3 autoantibodies in cardiovascular disease!

academic.oup.com/eurheartj/adva…

#cardioprotective #therapy #autoantibodies #G-protein #receptors #cardiotwitter <a href="/escardio/">European Society of Cardiology</a> @ESC_journals
JACC Journals (@jaccjournals) 's Twitter Profile Photo

#CVCT2023 #JACCHF SimPub: Meta-analysis of all randomized controlled trials in #HeartFailure. IV iron reduces both CV-death and HF-readmissions. But it might be time to redefine our definition of iron deficiency based on TSAT. bit.ly/3N5qfU4 CVCT - CardioVascular Clinical Trialists Pieter Martens

#CVCT2023 #JACCHF SimPub: Meta-analysis of all randomized controlled trials in #HeartFailure. IV iron reduces both CV-death and HF-readmissions. But it might be time to redefine our definition of iron deficiency based on TSAT. bit.ly/3N5qfU4

<a href="/CVCTForum/">CVCT - CardioVascular Clinical Trialists</a> <a href="/PieterMartensMD/">Pieter Martens</a>
Cardiovascular Research Foundation (@crfheart) 's Twitter Profile Photo

🚨 Act Fast! 🕒 Deadlines for #THT2024 Call for Science are right around the corner! 👉 Submit abstracts, fellows abstracts, fellows challenging cases, and THT Shark Tank Innovation Competition by Dec. 4, 2PM ET. 👉 Submit late-breaking clinical science/first-in-human and early

🚨 Act Fast! 🕒 Deadlines for #THT2024 Call for Science are right around the corner!

👉 Submit abstracts, fellows abstracts, fellows challenging cases, and THT Shark Tank Innovation Competition by Dec. 4, 2PM ET.

👉 Submit late-breaking clinical science/first-in-human and early
American College of Cardiology (@accintouch) 's Twitter Profile Photo

Q: Is intravenous iron beneficial for patients with #heartfailure and iron deficiency? A: In patients with HF and iron deficiency, treatment with IV iron can reduce CV deaths and HF hospitalizations. bit.ly/4aL4MKs #JACCHF

Q: Is intravenous iron beneficial for patients with #heartfailure and iron deficiency?

A: In patients with HF and iron deficiency, treatment with IV iron can reduce CV deaths and HF hospitalizations.

bit.ly/4aL4MKs #JACCHF
Myocarditis Fndn (@myocarditisfndn) 's Twitter Profile Photo

The MF is thrilled to announce one of the 2023 Fellowship Grant recipients, Dr. Simon Vanhentenrijk, MD, Pharm D, of the Cleveland Clinic! Read about his work below. myocarditisfoundation.org/the-myocarditi…

JACC Journals (@jaccjournals) 's Twitter Profile Photo

The new #JACCHF issue is now out! Hemodynamic gain index and peak rate pressure product can identify patients w/ #HFrEF at risk of poor clinical outcomes. This allows prognostication of #HeartFailure even when CPET is not available. bit.ly/49p3hjk #CHF W. H. Wilson Tang, MD

The new #JACCHF issue is now out!

Hemodynamic gain index and peak rate pressure product can identify patients w/ #HFrEF at risk of poor clinical outcomes. This allows prognostication of #HeartFailure even when CPET is not available. bit.ly/49p3hjk

#CHF <a href="/WilsonTangMD/">W. H. Wilson Tang, MD</a>
Eric Topol (@erictopol) 's Twitter Profile Photo

Niacin, the B vitamin that was previously used to improve lipid profile and reduce the risk of heart disease, promotes arterial inflammation and cardiovascular risk through its metabolites nature.com/articles/s4159… Nature Medicine

Niacin, the B vitamin that was previously used to improve lipid profile and reduce the risk of heart disease, promotes arterial inflammation and cardiovascular risk through its metabolites
nature.com/articles/s4159…
<a href="/NatureMedicine/">Nature Medicine</a>
W. H. Wilson Tang, MD (@wilsontangmd) 's Twitter Profile Photo

Great start with our fearless leader Dan Burkhoff MD PhD kicking off exciting #THT2024 with 3 days of packed agenda and exciting discussions in #heartfailure innovations.

Great start with our fearless leader <a href="/BurkhoffMd/">Dan Burkhoff MD PhD</a> kicking off exciting #THT2024 with 3 days of packed agenda and exciting discussions in #heartfailure innovations.